(AMGN) Amgen - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NASDAQ (USA) | Market Cap: 182.207m USD | Total Return: 23.8% in 12m
Avg Turnover: 894M
EPS Trend: 97.1%
Qual. Beats: 0
Rev. Trend: 98.7%
Qual. Beats: 0
Warnings
Altman Z'' 0.15 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Amgen Inc. is a global biotechnology company focused on the discovery, development, and manufacture of human therapeutics. Its extensive product portfolio targets chronic and life-threatening conditions, including cardiovascular disease, oncology, bone health, and inflammation. Key commercial assets include Enbrel, Otezla, Prolia, and Repatha, which address large-scale patient populations in immunology and metabolic health.
The company operates within the high-barrier biotechnology sector, where growth is driven by heavy investment in R&D and the protection of intellectual property through long-term patents. Amgen utilizes a business model centered on large-scale biologic manufacturing and strategic collaborations with partners like AstraZeneca and UCB to mitigate clinical development risks and expand its global market reach.
Distribution is managed primarily through pharmaceutical wholesalers, serving a network of hospitals, clinics, and pharmacies. Investors looking to evaluate the companys long-term valuation metrics can find further data on ValueRay. Founded in 1980, Amgen remains one of the worlds largest independent biotechnology firms by revenue and market capitalization.
- MariMari clinical trial data for weight-loss drug determines long-term valuation upside
- Horizon Therapeutics acquisition integration drives rare disease revenue and margin expansion
- Biosimilar competition erodes market share for legacy products Enbrel and Neulasta
- Medicare drug price negotiations under Inflation Reduction Act impact portfolio profitability
- Expansion of cardiovascular franchise Repatha improves revenue mix and offsets patent cliffs
| Net Income: 7.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.92 > 1.0 |
| NWC/Revenue: 17.51% < 20% (prev 11.49%; Δ 6.02% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.8b > Net Income 7.80b |
| Net Debt (45.3b) to EBITDA (16.7b): 2.72 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (544.0m) vs 12m ago 0.55% < -2% |
| Gross Margin: 71.46% > 18% (prev 0.63%; Δ 7.08k% > 0.5%) |
| Asset Turnover: 40.95% > 50% (prev 38.19%; Δ 2.76% > 0%) |
| Interest Coverage Ratio: 4.36 > 6 (EBITDA TTM 16.7b / Interest Expense TTM 2.70b) |
| A: 0.07 (Total Current Assets 31.5b - Total Current Liabilities 25.0b) / Total Assets 92.5b |
| B: -0.27 (Retained Earnings -24.6b / Total Assets 92.5b) |
| C: 0.13 (EBIT TTM 11.8b / Avg Total Assets 90.9b) |
| D: -0.30 (Book Value of Equity -24.6b / Total Liabilities 83.3b) |
| Altman-Z'' = 0.15 = B |
| DSRI: 1.03 (Receivables 9.14b/8.13b, Revenue 37.2b/34.1b) |
| GMI: 0.88 (GM 71.46% / 63.00%) |
| AQI: 0.92 (AQ_t 0.57 / AQ_t-1 0.62) |
| SGI: 1.09 (Revenue 37.2b / 34.1b) |
| TATA: -0.03 (NI 7.80b - CFO 10.8b) / TA 92.5b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 335.94 with a total of 1,691,562 shares traded.
Over the past week, the price has changed by +3.56%,
over one month by -0.50%,
over three months by -10.77% and
over the past year by +23.83%.
Amgen has received a consensus analysts rating of 3.63. Therefore, it is recommended to hold AMGN.
- StrongBuy: 10
- Buy: 5
- Hold: 14
- Sell: 1
- StrongSell: 2
| Analysts Target Price | 352.2 | 4.8% |
P/E Trailing = 23.4809
P/E Forward = 15.1745
P/S = 4.8954
P/B = 19.8266
P/EG = 2.2301
Revenue TTM = 37.2b USD
EBIT TTM = 11.8b USD
EBITDA TTM = 16.7b USD
Long Term Debt = 51.9b USD (from longTermDebt, last quarter)
Short Term Debt = 5.44b USD (from shortTermDebt, last quarter)
Debt = 57.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.3b USD (calculated: Debt 57.3b - CCE 12.0b)
Enterprise Value = 227b USD (182b + Debt 57.3b - CCE 12.0b)
Interest Coverage Ratio = 4.36 (Ebit TTM 11.8b / Interest Expense TTM 2.70b)
EV/FCF = 26.46x (Enterprise Value 227b / FCF TTM 8.60b)
FCF Yield = 3.78% (FCF TTM 8.60b / Enterprise Value 227b)
FCF Margin = 23.09% (FCF TTM 8.60b / Revenue TTM 37.2b)
Net Margin = 20.95% (Net Income TTM 7.80b / Revenue TTM 37.2b)
Gross Margin = 71.46% ((Revenue TTM 37.2b - Cost of Revenue TTM 10.6b) / Revenue TTM)
Gross Margin QoQ = 68.16% (prev 81.91%)
Tobins Q-Ratio = 2.46 (Enterprise Value 227b / Total Assets 92.5b)
Interest Expense / Debt = 4.72% (Interest Expense 2.70b / Debt 57.3b)
Taxrate = 12.72% (265.0m / 2.08b)
NOPAT = 10.3b (EBIT 11.8b * (1 - 12.72%))
Current Ratio = 1.26 (Total Current Assets 31.5b / Total Current Liabilities 25.0b)
Debt / Equity = 6.24 (Debt 57.3b / totalStockholderEquity, last quarter 9.19b)
Debt / EBITDA = 2.72 (Net Debt 45.3b / EBITDA 16.7b)
Debt / FCF = 5.27 (Net Debt 45.3b / FCF TTM 8.60b)
Total Stockholder Equity = 8.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.58% (Net Income 7.80b / Total Assets 92.5b)
RoE = 23.37% (Net Income TTM 7.80b / Total Stockholder Equity 33.4b)
RoCE = 13.81% (EBIT 11.8b / Capital Employed (Equity 33.4b + L.T.Debt 51.9b))
RoIC = 14.11% (NOPAT 10.3b / Invested Capital 72.9b)
WACC = 6.11% (E(182b)/V(240b) * Re(6.74%) + D(57.3b)/V(240b) * Rd(4.72%) * (1-Tc(0.13)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.22 | Cagr: 0.33%
[DCF] Terminal Value 73.10% ; FCFF base≈9.52b ; Y1≈8.35b ; Y5≈6.75b
[DCF] Fair Price = 116.7 (EV 108b - Net Debt 45.3b = Equity 63.0b / Shares 540.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 97.13 | EPS CAGR: 9.35% | SUE: -0.03 | # QB: 0
Revenue Correlation: 98.67 | Revenue CAGR: 14.06% | SUE: 0.23 | # QB: 0
EPS current Quarter (2026-06-30): EPS=5.59 | Chg30d=-3.18% | Revisions=-60% | Analysts=26
EPS next Quarter (2026-09-30): EPS=5.76 | Chg30d=-0.88% | Revisions=-36% | Analysts=26
EPS current Year (2026-12-31): EPS=22.41 | Chg30d=+0.21% | Revisions=+24% | GrowthEPS=+2.6% | GrowthRev=+2.8%
EPS next Year (2027-12-31): EPS=23.48 | Chg30d=+0.66% | Revisions=+10% | GrowthEPS=+4.8% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -60%